Alessia Petrocchi,Alina Ciammaichella
Alessia Petrocchi
Introduction: SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2) is a target of interest for cancer therapy due to its key role in the regulation of the RAS/MAPK signal transduction pathway downstream ...
Anushka Sharma,Rahul Dubey,Shankar Gupta et al.
Anushka Sharma et al.
Introduction: PIM Kinases (PIM-1, PIM-2, and PIM-3) have been reported to play crucial role in signaling cascades that govern cell survival, proliferation, and differentiation. Over-expression of these kinases leads to he...
Clemente Capasso,Claudiu T Supuran
Clemente Capasso
Introduction: This review offers an updated perspective on the biomedical applications of prokaryotic carbonic anhydrases (CAs), emphasizing their potential as targets for drug development against antibiotic-resistant bac...
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021-December 2023) [0.03%]
选择性雌激素受体降解剂（SERD）和共价拮抗剂（Serca）的专利回顾（2021年7月-2023年12月）
James S Scott,Teresa C M Klinowska
James S Scott
Introduction: Breast cancer is the most frequently diagnosed cancer worldwide. With around 70% of breast cancers expressing the estrogen receptor (ER), molecules capable of antagonizing and degrading ER (SERDs) or covalen...
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present) [0.03%]
2018年至今P2X7受体拮抗剂治疗炎症疾病的专利分析
Jamshed Iqbal,Sehrish Bano,Imtiaz Ali Khan et al.
Jamshed Iqbal et al.
Introduction: The purinergic P2X7 receptor (P2X7R) is expressed on the surface of many different types of cells, including immune cells. Targeting P2X7R with antagonists has been studied for its potential therapeutic effe...
Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update [0.03%]
一种Ⅱ型和Ⅲ型肌动蛋白受体酪氨酸激酶抑制剂的专利更新（2020-2022）
Petar Iliev,Carolin Jaworski,Carmen Wängler et al.
Petar Iliev et al.
Introduction: The Trk family proteins are membrane-bound kinases predominantly expressed in neuronal tissues. Activated by neurotrophins, they regulate critical cellular processes through downstream signaling pathways. Dy...
Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents [0.03%]
蛋白激酶抑制剂：二十年的成功、新的挑战和最近的专利发展趋势
Mourad A M Aboul-Soud,Yazeed A Al-Sheikh,Hazem K Ghneim et al.
Mourad A M Aboul-Soud et al.
Introduction: Protein kinases (PKs) play key roles in cellular signaling and regulation cascades and therefore are listed among the most investigated enzymes with the intent to develop drugs that are able to modulate thei...
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023 [0.03%]
合成致死性：在SMARCA4缺陷型肿瘤中靶向SMARCA2溴结构域降解——2019年-2023年6月专利文献综述
Esther C Y Lee,Kyle D Reichl,Ariamala Gopalsamy
Esther C Y Lee
Introduction: SMARCA2 and SMARCA4 are subunits of the SWI/SNF complex which is a chromatin remodeling complex and a key epigenetic regulator that facilitates gene expression. Tumors with loss of function mutations in SMAR...
Giuseppina De Simone,Claudiu T Supuran
Giuseppina De Simone
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans, the pivotal pathogens in the oral cavity [0.03%]
过去五年关于牙周病关键致病菌的专利分析——以齿龈卟啉单胞菌和变异链球菌为例
Bianca Laura Bernardoni,Ilaria D&#x;Agostino,Concettina La Motta et al.
Bianca Laura Bernardoni et al.
Introduction: The oral cavity harbors an extensive array of over 700 microorganisms, forming the most complex biome of the entire human body, with bacterial species being the most abundant. Oral diseases, e.g. periodontit...